Scientific Research Publishing

Advances in Chemical Engineering and Science, 2024, 14, 155-171
https://www.scirp.org/journal/aces
ISSN Online: 2160-0406
ISSN Print: 2160-0392

# Fast-to-Clinic, Fast-to-Market in Biotech Innovation: Optimizing Chemistry Manufacturing & Controls (CMC) Excellence for Clinical and Commercial Success

**Kishore Kumar Hotha**

Veranova, Devens, MA, USA
Email: drhotha@gmail.com

**How to cite this paper:** Hotha, K.K. (2024) Fast-to-Clinic, Fast-to-Market in Biotech Innovation: Optimizing Chemistry Manufacturing & Controls (CMC) Excellence for Clinical and Commercial Success. *Advances in Chemical Engineering and Science*, **14**, 155-171.
https://doi.org/10.4236/aces.2024.143010

**Received:** June 28, 2024
**Accepted:** July 21, 2024
**Published:** July 24, 2024



## Abstract

In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical "mantra" for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market. The article delves into the intricacies of implementing a fast-to-clinic/market strategy, underlining the empowering role of strategic decision-making in preclinical and commercial stages. The plan advocates for a phase-appropriate approach, where the development decision is tailored to each phase of the product's lifecycle. This ensures that resources are allocated efficiently, risks are managed effectively, and the product can move through the development pipeline accelerated without compromising quality or regulatory compliance. The article also discusses the role of CDMOs in facilitating rapid product development and the essential factors biotech companies must consider when selecting a partner for outsourcing. These factors include the CDMO's expertise in navigating regulatory landscapes, technological capabilities, and ability to scale processes efficiently. Moreover, the article stresses the importance of agility and flexibility in the fast-to-clinic/market approach. Biotech companies are encouraged to adopt adaptable strategies that respond to the fast-evolving regulatory and market landscapes.

## Keywords

Fast to Clinic, Innovation, CDMO, CMC, Preclinical, FDA, IND, NDA, ANDA, Biotech

## 1. Introduction

In the dynamic range of pharmaceutical research, an increasing number of small to medium-sized biotech firms, many of which operate virtually, are playing a pivotal role in the early stages of drug development. These organizations typically focus not on bringing new drugs to market but on reaching key milestones such as submitting investigational new drug (IND) applications or leveraging their intellectual property (IP) for acquisition deals. Given these companies' unique goals and constraints, including timing, financial resources, and regulatory requirements, their approach to Chemistry, Manufacturing, and Controls (CMC) must be highly customized. The strategic use of external advisors and contract manufacturing organizations (CMOs) is critical in crafting CMC strategies tailored to each company's needs and objectives [1] [2].

Navigating the path from discovery to the market is incredibly challenging for these burgeoning biotech firms, with only a select number of molecules making it past Phase III clinical trials. This indicates a high rate of early attrition, often attributed to the complexities associated with CMC. This document examines the strategic planning essential for effectively managing the CMC landscape from early development to commercialization [3]. The swift development of COVID-19 vaccines, accomplished in less than a year, is a monumental achievement in the field, prompting a reevaluation of drug development timelines industry-wide. This reevaluation aims to discover methods to expedite development phases while adhering to safety, effectiveness, and regulatory compliance standards. This document further investigates the strategies, challenges, and possible avenues to infuse speed into the drug development process, carefully weighing the trade-offs between quick advancements, patient safety, and the financial implications inherent in the pharmaceutical industry [4].

Approximately 6% of molecules progress from their discovery phase to phase III clinical trials. The failure of the remaining 94% to advance highlights a considerable hurdle in the initial stages of drug development, often linked to various factors not limited to CMC [5]. The scope of CMC includes establishing manufacturing protocols, determining the product's characteristics, and creating testing procedures to guarantee each batch's safety, efficacy, and consistency. Early attention to these critical CMC factors is essential to reduce the likelihood of later-stage setbacks (**Figure 1**). The push for quicker development timelines escalates financial risks, with the cost of introducing a new medication to the market averaging over $2 billion, primarily due to the substantial number of failed clinical trials [6]. Careful selection of drug candidates with promising prospects and the strategic distribution of resources are crucial for balancing these risks, giving precedence to treatments with a higher chance of successful clinical outcomes [7]. The "Fastlane" strategy presents an approach to expedite the development of promising drugs through aggressive and proactive planning to reduce market entry times. This strategy requires engaging in costly concurrent activities, preparing for clinical trial phases in advance, and allocating




**Figure 1.** Overview of the discovery to preclinical process.

resources to critical projects selectively. Nevertheless, executing this strategy demands meticulous attention to maintaining patient safety, complying with regulatory requirements, and rationalizing the expenses of speeding up development. It is imperative for the success of the "Fastlane" approach to find an equilibrium between the need for swift development and the obligation to produce safe, efficient, and regulatory-compliant medical treatments.

## 2. FDA Overview on Fast-to-Clinic Approach

The five special FDA designations—orphan, Fast Track, Accelerated Approval, Priority Review, and Breakthrough Therapy—play vital roles in streamlining the development and approval of medications that address severe medical conditions with unmet needs. Each designation uniquely supports quicker transitions from development phases to market or clinical use, significantly benefiting healthcare providers and patients (**Table 1**) [7] [8].

Orphan Designation is awarded to drugs targeting diseases affecting fewer than 200,000 people in the U.S. It offers incentives like tax credits and extended exclusivity, promoting the development of treatments for rare diseases that might not otherwise be economically feasible. Fast Track targets drugs addressing severe conditions lacking adequate therapies. It facilitates more frequent communication with the FDA, enabling a rolling review process that can significantly cut the time to market by allowing sequential submission of sections of a drug application. Accelerated Approval can be granted to drugs that significantly improve existing treatments based on surrogate endpoints, allowing earlier market entry pending confirmation of clinical benefits in post-marketing studies.

Priority Review reduces the FDA review time from ten months to six for drugs that demonstrate significant advances in treating or diagnosing severe conditions, thereby expediting their availability. Breakthrough Therapy is designed for drugs that improve over existing therapies on crucial clinical endpoints. This

Table 1. Overview of FDA designation on fast to clinic.

| FDA Designation | Focus | Benefits | Impact on Development |
|---|---|---|---|
| Orphan | Drugs for rare diseases (under 200,000 affected in the U.S.) | Tax credits, user fee waivers, extended exclusivity | Encourages investment in rare diseases with small markets; supports tailored clinical trial designs and early FDA engagement. |
| Fast Track | Severe conditions with unmet medical need | More frequent FDA meetings, eligibility for Accelerated Approval, and Priority Review | Allows rolling review of data submissions; accelerates clinical development and review phases. |
| Accelerated Approval | Severe conditions can use surrogate endpoints. | Approval based on surrogate endpoints, followed by post-marketing studies to confirm benefits | Shortens time to market by allowing earlier approval; necessitates post-approval trials to verify benefits. |
| Priority Review | Significant improvements in the treatment of severe conditions | Shortened review period from 10 months to 6 months | Reduces FDA review time, expediting the overall approval process. |
| Breakthrough Therapy | Substantial improvement over existing therapies | All Fast Track benefits plus intensive FDA guidance | It streamlines drug development with more FDA interaction, potentially facilitating quicker progression through clinical trials to approval. |

designation includes all the benefits of Fast Track, plus intensive FDA guidance, which enhances the efficiency of drug development processes. These designations are crucial in aligning drug development with regulatory standards, ensuring faster and more efficient clinical trials, and swiftly bringing vital drugs to the market to meet patient needs.

## 3. Fast to Clinic—Enabling IND Studies

The IND submission process is a critical gateway for new drugs, marking their transition from preclinical development to human clinical trials. It embodies a comprehensive evaluation mechanism that ensures only those drug candidates with demonstrated safety and a preliminary indication of efficacy proceed to clinical evaluation (Table 2).

## 4. Requirements for IND

Requirements for IND are very crucial in designing the fast-to-clinic approach. For an IND submission, a comprehensive dossier is meticulously crafted to meet the stringent regulatory standards set forth by authorities such as the U.S. Food and Drug Administration (FDA). This submission encompasses detailed preclinical study data, including pharmacological, toxicological, and pharmacokinetic evaluations, to demonstrate the investigational product's safety and rationale for human trials [9]. Additionally, it necessitates including CMC information detailing the synthesis, characterization, and quality control measures of both the drug substance and the drug product, ensuring their consistency and safety. The dossier also requires a proposed clinical trial protocol outlining the study design, objectives, and methodology, along with information on the qualifications

Table 2. Overview of IND requirements.

| Requirement Category | Description |
|---|---|
| Preclinical Studies | Pharmacological and toxicological studies to assess safety and efficacy.<br>Pharmacokinetics studies to understand the drug's behavior within the body. |
| Chemistry, Manufacturing, and Control (CMC) Information | Detailed information on the drug substance and drug product's synthesis, purification, and characterization.<br>Quality control measures and stability data. |
| Drug Substance Development | Synthesis and characterization of the drug substance.<br>Stability under various conditions.<br>Identification and control of impurities. |
| Drug Product Development | Formulation development, including excipient selection.<br>Description of the manufacturing process and scale-up.<br>Packaging methods and stability data. |
| Clinical Trial Protocol | A detailed plan of the proposed clinical trial(s), including study design, objectives, and methodology.<br>Information on the qualifications of clinical investigators.<br>Copies of informed consent forms. |
| Regulatory Documents | All necessary forms and documents required by the regulatory authority (e.g., FDA Form 1571, 1572).<br>Any additional documentation requested by the regulatory authority. |

of clinical investigators and informed consent forms for trial participants. This elaborate compilation of data and documentation is pivotal in obtaining the regulatory green light to proceed with clinical trials, marking a critical step in drug development [10].

Accelerating processes is possible by optimizing supply chains, refining project management, implementing automation, engaging in outsourcing, managing inventory efficiently, and leveraging technology/Artificial Intelligence collaborations. Certain enterprises can also launch "minimum requirements" to gain early access to drug development, subsequently refining these offerings based on growth and clinical phases. While these strategies may apply to some extent within drug development, initially releasing a minimum viable product is incompatible with this field [11].

Adopting a comprehensive fast-to-clinic strategy that includes efficient coordination between biotech companies and CDMOs is essential to streamline the journey from discovery to clinic. This approach focuses on leveraging available data, optimizing development processes, and engaging regulatory bodies early. Streamlined synthesis, formulation development, and a focus on early CMC activities are pivotal for addressing manufacturing challenges upfront. Adaptive trial designs and strategic use of regulatory pathways such as Fast Track or Priority Review can significantly reduce development timelines. Outsourcing to CDMOs and robust project management further accelerate progress by leveraging external expertise and ensuring that projects stay on track. Coordination efforts are centered around early engagement with CDMOs, forming integrated teams, and maintaining transparent communication to facilitate information exchange and decision-making. This integrated approach ensures that develop-

ment plans are robust, scalable, and regulatory-compliant, speeding up the time to reach clinical trials (Table 3) [12] [13].

Table 3. Fast-to-clinic strategy and coordination table.

| Strategy | Description | Benefits | Development Challenges |
|---|---|---|---|
| Supply Chain Optimization | Streamline supply chains for quicker deliveries | Enhances efficiency, cuts lead times | Regulatory constraints on rapid changes |
| Project Management Optimization | Improve project management techniques | Increases focus, minimizes bottlenecks | Limited flexibility due to regulations |
| Technological Automation | Deploy automation for increased efficiency | Boosts productivity, minimizes errors | High setup costs, stringent validations |
| Strategic Outsourcing | Collaborate for specialized expertise and resources | Expands capabilities, lowers investments | Issues with quality, compliance, and IP |
| Inventory Efficiency | Refine inventory management for optimal operations | Lowers waste, enhances planning | Strict regulatory norms on inventory |
| Digital Collaboration | Leverage digital platforms for better collaboration | Improves communication and data sharing | Concerns over data security and compliance |
| Iterative Development | Implement a minimum viable product strategy | Speeds-up execution allows refinements | Variability in complexity and applicability |
| Data Utilization | Accelerate processes by using existing data | Shortens preclinical stages guide trials | Limitations of data applicability and acceptance |
| Synthesis & Formulation Streamlining | Simplify synthesis and formulation processes | Reduces development time and costs | Feasibility issues with complex molecules |
| Proactive CMC Integration | Begin CMC processes early to prevent setbacks | Prevents delays, enhances scalability | Requires substantial initial planning |
| Adaptive Clinical Trials | Use flexible trial designs to adapt to findings | Enables adjustments, shortens timelines | Requires intricate management and analysis |
| Proactive Regulatory Interaction | Early engagement with regulatory bodies | Potentially speeds up approval processes | Demands precise communication, resource-heavy |
| Expedited Regulatory Pathways | Utilize fast-track approval processes for urgent needs | Quickens market entry for critical drugs | Highly stringent scrutiny and eligibility |
| CDMO Collaboration | Employ CDMOs for their specific expertise | Access to specialized resources | Risks of dependency and strategic misalignment |
| Cross-functional Teamwork | Form interdepartmental teams for synergy | Streamlines problem-solving unifies objectives | Challenges in cross-functional management |
| Open Communication Channels | Promote transparency in communications | Enhances alignment and decision-making | It needs a culture of openness and frequent updates |

## 5. IND to NDA—Clinical Studies and Fast-to-Market Approach

Following IND approval, the initial phase entails conducting phase 1 clinical studies to evaluate human safety and efficacy. These studies involve healthy vo-

lunteers, necessitating a strategy finely tuned to the specifics of drug development. Specific focal points emerge given the early-stage nature of process optimization and control within the CMC sections [14]. These include revisiting existing data, assessing manufacturing capabilities, leveraging technical expertise, optimizing processes, and implementing impurity controls. The extent of these activities at each phase must be meticulously calibrated, considering factors such as clinical significance, required drug designation, and the urgency of a fast-to-clinic approach. Coordination with CDMOs is integral throughout this process [15].

Safety and efficacy remain paramount at every stage of drug development. Thus, it is crucial to establish clear expectations for each developmental phase, prioritizing streamlined activities over excessive front-loading in the early stages. This approach ensures focused progression aligned with regulatory standards and the goal of delivering safe and effective therapeutics [16]. Moving from IND to NDA throughout all the preclinical phases, reviewing the CMC development at each phase was recommended. **Table 4** is an example of the general considerations moving from early to late phases. The "Minimum Requirements in Early Phase" column describes what is necessary during the early phase of drug development. In contrast, the "Add-on Requirements in Late Phase" column details the additional requirements that become relevant as the drug progresses to later stages of development [17].

In the early phase, the focus is on establishing a foundation for safe and effective drug development, with sufficient flexibility to make changes as more data becomes available. The late phase adds to the need for rigorous validation, scalability for commercial production, and adherence to strict regulatory standards to ensure consistent quality and safety for widespread use (**Figure 2**).

**Table 4.** Development stage-specific requirements for pharmaceutical products.

| Early Phase (Pre-Clinical to Phase IIA) | Minimum Requirements in the Early Phase | Late Phase (Phase IIB to Commercial) | Add-on Requirements in Late Phase |
|---|---|---|---|
| Toxicology and Safety Assessment | They limited toxicology data to inform safety assessment and initial handling requirements. | EHS Compliance | Comprehensive toxicological data is needed to refine safety protocols, meet regulatory EHS standards, and establish final handling practices. |
| API Solid-State Properties | Initial characterization of polymorphs and salt forms. | API Specifications and Scale-Up | Detailed understanding of API properties to set specifications, control polymorphism, and ensure scalability. |
| Raw Materials and Excipients | Selection based on compatibility with API and availability for early stages. | Supply Chain Management | Secure reliable, scalable sourcing and establish quality agreements with suppliers for long-term supply. |
| Formulation and Process Design | Early phase-appropriate formulations focus on stability and scalability. | Formulation Optimization | Develop formulations suitable for large-scale manufacturing and commercial distribution. |

**Continued**

| | | | |
|---|---|---|---|
| Analytical Methods | Phase-appropriate methods for early characterization and stability. | Method Validation and Transfer | Fully validate analytical methods and ensure transferability to different labs or sites. |
| Development History | Documentation of development rationale and decision-making. | Regulatory Documentation | Detailed documentation for regulatory submissions, including development history and risk mitigation. |
| Drug Substance Synthesis | Synthesis route established for small-scale production. | Process Optimization and Validation | Optimize synthesis for large-scale production, validate processes, and ensure reproducibility. |
| Process Analytical Technology (PAT) | Implementation for in-process monitoring and control. | PAT System Maturation | Expand PAT usage for real-time release testing and tighter process control. |
| Pilot Batch Production | Small-scale batches to demonstrate proof of concept and initial safety. | Commercial Batch Production | Scale-up to commercial batch sizes, ensuring GMP compliance and batch-to-batch consistency. |
| Stability Studies | Short-term stability to support clinical trial application. | Long-term Stability and Degradation Studies | Long-term stability to establish shelf life, perform stress tests, and meet regulatory requirements for commercialization. |
| Extractables and Leachable (E&L) | Preliminary assessment to ensure initial product safety. | Comprehensive E&L Testing | Detailed E&L studies to identify and quantify potential impurities from the final production environment. |
| Cleaning Validation | Establish initial cleaning procedures for equipment. | Full-Scale Cleaning Validation | Validate cleaning procedures to prevent cross-contamination and meet cGMP standards for commercial production. |
| Batch Release Testing | Small-scale batch testing for internal decision-making. | GMP Batch Release Testing | Full-scale GMP batch release testing is needed to confirm that each batch meets regulatory and commercial specifications. |
| | | Continuous Process Verification | Ongoing verification to ensure the manufacturing process remains in a state of control during commercial production. |




**Figure 2.** Overview of phase appropriate strategy.

## 6. Navigating CMC Development for Emerging Biotech

For emerging biotech companies, mastering the complex landscape of CMC development is pivotal in transitioning from early-stage innovation to commercial success. The initial phases focus on establishing a solid foundation through meticulous risk mitigation and adherence to regulatory and industry standards without compromising essential CMC activities. These early stages are fundamental to accurate toxicology assessments and a thorough understanding of the API solid-state properties. Additionally, formulating processes with scalability is crucial to ensure seamless and efficient transitions from clinical to commercial stages [18].

As development advances into late-stage and commercial phases, the importance of scalability and advanced analytical methods becomes increasingly pronounced. Transitioning from disposable process trains to multi-product, commercial-scale process trains is essential to accommodate growing production demands. This stage also necessitates the evolution of analytical methods to be robust and stability-indicating, which are crucial for maintaining regulatory compliance and ensuring product stability. Comprehensive documentation throughout this phase facilitates smoother regulatory reviews and approvals, streamlining the transition into commercial manufacturing (**Table 4**) [19].

A strategic partnership with a CDMO is a cornerstone of the CMC development journey. Selecting a CDMO that aligns well with the molecule's requirements from early to late phases can significantly enhance operational speed, reduce overhead, and ensure streamlined knowledge transfer. These collaborations are tailored to address the unique challenges of each phase, recognizing that a one-size-fits-all approach is insufficient. By planning early, meticulously documenting development processes, and customizing CMC activities to fit specific timelines, funding limitations, and regulatory frameworks, biotech companies can navigate the path to commercialization with greater assurance and efficiency (**Table 5**) [20].

### 6.1. Strategic Financing in Biotech Development

Funding critically shapes the operational decisions of small biotech companies. These organizations must expertly navigate the delicate balance between essential development activities that cannot be postponed and those that can be temporarily deferred when funding is limited. This balancing act is crucial as securing adequate financing supports ongoing development and ensures that regulatory activities, which are vital for long-term success, are not compromised. Practical strategies might include prioritizing core development activities directly impacting regulatory success and exploring alternative funding sources, such as partnerships or venture capital, to sustain other necessary operations without delay.

### 6.2. Navigating Regulatory Landscapes for Drug Approval

Regulatory assurance is a non-negotiable aspect of the drug development process. For investigational new drug applications, regulators require comprehensive

Table 5. Bridging the gap: Key considerations for early to late-phase pharmaceutical development.

| Key Area | Early Phase Focus | Transition to Late Phase | Long-term Commercial Strategy |
|---|---|---|---|
| Decision Making | Risk-based decisions to balance short-term goals with long-term planning. | Decisions must maintain the required CMC work for regulatory compliance. | Strategic planning for IP sale or company acquisition. |
| API Properties | Initial understanding of polymorphs and crystallinity for scale-up. | Detailed characterization to set API specifications. | Contingency plans for rework or redevelopment of methods. |
| Materials & Vendors | Selection of raw materials and vendors based on compatibility and availability. | Considerations for scalability and long-term supply agreements. | Ensuring quality and uninterrupted supply for commercialization. |
| Regulatory Compliance | Adherence to basic regulatory guidelines for early development. | Increasing substantiation and detail as development progresses. | Comprehensive documentation for full regulatory approval. |
| CDMO Partnership | Aligning with CDMOs that understand the molecule's early-phase needs. | Seamless transition and knowledge transfer between phases. | Integrated services for consistent quality throughout the market. |
| Manufacturing Adaptability | Single-use systems or flexible process trains are used for initial production. | Transition to scalable, multi-product trains. | Readiness for full-scale commercial manufacturing. |
| Analytical Method Evolution | Developing phase-appropriate analytical methods. | Adaptation and validation of methods for later stages. | Development of robust, commercial-grade analytical methods. |
| Documentation | Documenting decision-making and risk mitigation strategies. | Detailed development history for regulatory purposes. | Maintaining a comprehensive knowledge base for the product. |
| Proactive Commercial Planning | Consideration for future commercialization in formulation and process design. | Addressing scale-up and technology transfer. | Strategy for market access and distribution. |
| Tailored CMC Programs | Custom CMC strategies to meet the company's specific goals. | Adjusting programs based on the molecule's progression. | Adapting CMC strategies for large-scale operations. |
| Quality vs. Speed | Balancing rapid development with maintaining product quality. | Mitigating risks that could lead to delays or increased costs. | Quality assurance in line with accelerated timelines. |
| Resource Allocation | Strategic use of funding and expertise to meet development milestones. | Efficient use of resources to avoid unnecessary expenditure. | Optimal investment in critical areas for market readiness. |
| Technology Transfer | Disciplined approach to technology transfer to late-phase CDMO partners. | Addressing potential issues in technology transfer to avoid delays. | Ensuring smooth scale-up to commercial manufacturing. |
| Integrated Solutions | Seeking CDMOs with integrated early-phase solutions. | Leveraging CDMO expertise to reduce risks during phase transitions. | Utilizing comprehensive CDMO services for market launch. |

data detailing the synthesis or fermentation of the drug substance, along with its characterization, testing methodologies, and stability. Drug product formulations and phase-appropriate stability tests must also be established and documented. In practice, biotech companies must invest in thorough early-phase testing and data collection to build a robust foundation for regulatory submis-

sions, ensuring that each step of the process is well-documented and meets the stringent requirements of regulatory bodies [21].

### 6.3. Optimizing CMO Partnerships in Biotech

Small biotech firms often rely on CMOs to handle their CMC activities. This outsourcing demands meticulous management to keep the development timeline on track. This involves establishing clear communication channels and setting precise expectations with CMOs to ensure all parties understand the timelines and critical milestones. Managing these relationships effectively is crucial, as delays or miscommunications can directly impact the supply of clinical trial materials and the support of subsequent applications [22].

As contract service providers (CSPs) use increases, biotech companies must adopt new operational strategies to ensure compliance with quality regulations and maintain patient safety and data integrity accountability. Practically, this means that the primary license holder must oversee all operations, regardless of how many external parties are involved. This includes establishing robust oversight mechanisms and ensuring that CSPs adhere to the same quality standards as the contracting company to prevent compliance or data integrity lapses [23].

### 6.4. Tailoring Development Strategies to Clinical Phases

The FDA and other regulatory bodies recommend tailoring CMC development to the phase of clinical trials, although they may not provide detailed requirements for each phase. This implies that early development might require less extensive data collection and validation than later phases. Companies must carefully plan their development strategy to avoid unnecessary costs and efforts in early phases while ensuring they are prepared to scale up and validate methods as the product advances. This strategic planning helps prevent the need for re-development later, which can be costly and time-consuming.

### 6.5. Balancing Speed and Quality in Drug Development

Balancing speed and quality is crucial in the competitive and fast-paced pharmaceutical industry. Biotech companies sometimes need to accept calculated quality risks to accelerate development phases. However, by gathering comprehensive data before critical stages such as Phase III trials, companies can improve the efficiency of these trials and potentially reduce overall development time. This involves strategic decision-making to determine when accelerated timelines are worth the risk and when more thorough data collection will benefit the project in the long run.

## 7. Enhancing Clinical Readiness with CDMO Expertise

### 7.1. Optimized Development Timelines and Requirements for Clinical Stages

The development timing and requirements for progressing a pharmaceutical

product from preclinical stages through commercialization are meticulously planned to ensure efficiency and compliance with quality standards. Initially, the process involves a familiarization run-through on a small scale, typically less than 10 grams, which requires about one week per step across different development stages. As the scale increases, from kilo scale preparation (up to 100 liters) in both GMP and non-GMP environments to plant manufacturing, additional time is allocated for scaling up and ensuring quality, with increased time needed for plant manufacturing processes across all stages [21].

In preclinical and Phase I, the approach maintains a high-risk tolerance, emphasizing identifying key quality attributes of raw materials and tracking critical impurities. The process is designed to ensure purity through chromatography and stability under standard conditions. The requirements become more stringent as the product moves to Phase II and III. The focus shifts to optimizing the process through experimental verification, vendor qualification, and detailed design of experiments (DOE) [22]. The process parameters are increasingly optimized, and major impurities are managed with strategic hold points and assessments. By the commercial phase, the process is fully optimized to ensure robustness, minimal waste, and optimal yield, with all impurities identified and controlled, providing the drug's stability and efficacy for market release. This structured approach ensures compliance with regulatory standards and maximizes efficiency and productivity [23] (**Figure 3**).

### 7.2. Comprehensive Analytical Development from Preclinical to Commercialization

Analytical development in the pharmaceutical sector is a phased and structured approach that starts with a proactive risk assessment in the preclinical to Phase I stages. This approach ensures accuracy, compliance, and efficiency from the early stages to commercial production, setting a robust foundation for later




**Figure 3.** Integration of CDMO & biotech partners.

phases [24].

As the process transitions from Phase I to IIb, analytical procedures advance. This includes refining the ATP, conducting detailed risk assessments, finalizing parameter set points, and formally defining and validating the analytical procedure control strategy. Routine monitoring is emphasized to ensure ongoing compliance and performance [25] [26].

When development reaches Phase IIb, the approach becomes dynamic, focusing on continuous improvement and robust change management strategies. This includes updates to analytical control strategies, ongoing risk assessments, and product and testing strategy adjustments as necessary to align with scaling and commercialization efforts [25].

Concurrently, the analytical lifecycle from preclinical to Phase III is managed through three main stages: development, qualification, and validation. Each stage is characterized by specific goals, such as establishing methods in any lab during the development phase, enhancing method performance under quality oversight during qualification, and ensuring method suitability for routine use during validation in cGMP-accredited labs. These stages ensure that method performance meets development requirements, investigates nonconformities, and maintains stringent quality controls, all crucial for successful commercialization [27] [28] (**Figure 4**).




**Figure 4.** Analytical lifecycle process.

The structured approach to analytical development is not just a process but a reliable and effective method that ensures pharmaceutical products are developed under stringent quality controls. It involves thorough vetting at every stage of the development process, leading to the creation of effective and compliant market-ready products (**Figure 5**).

### 7.3. Streamlined Development for Rapid Market Entry

A strategy focusing on rapid progression from initial development to clinical stages emphasizes clarity and cost control. It involves specific plans for the scope




**Figure 5.** Analytical development phase appropriate strategy.

of work (SoW), including timelines and pricing, to ensure projects stay within budget. By adopting flexible approaches in the discovery phase and selecting the most viable formulations early on, the process seeks to minimize later modifications, speed up the development, and ensure intellectual property can be appropriately secured.

### 7.4. Enhanced Value through Customized Solutions

The approach leverages different costing models that clarify deliverables, timelines, and costs, thereby maintaining budget adherence. It features flexible solid form exploration early in the discovery phase, accelerating familiarization and scale-up processes. This strategy ensures a smoother regulatory development trajectory and caters to specific program needs through customizable analytical and chemical development options, enhancing cost-effectiveness.

### 7.5. Commercial Strategy for Early-Market Advantage

The commercial strategy is designed to attract early-phase clients through a well-structured proposal review and pricing strategy. By introducing a standardized template for SoW and a pricing model to leverage the project's total cost to provide more attractive early-phase proposals. It incorporates comprehensive chemical and analytical development strategies that streamline processes, ensure quality control from the onset, and facilitate a faster transition from development to clinical stages (**Figure 6**).




**Figure 6.** Integration of CMC strategies.

### 7.6. Comprehensive Offering to Expand Market Base

The holistic offering is designed to expand the customer base and build opportunities through a phase-appropriate approach. It integrates a standard proposal review process to ensure alignment with strategic objectives, optimized early developability assessment to lock in preferred forms, streamlined development to reduce process times, and tiered analytical development options that align with client needs. The production strategies are clarified early to ensure quality assurance and process control, complemented by a fixed fee pricing model that provides clear cost expectations.

## 8. Conclusion

Designing a phase-appropriate CMC strategy is crucial for the success of an emerging biotech company. It requires balancing multiple factors, including understanding the company's unique drivers and goals and aligning these with the specific requirements of the product being developed. The "one-size-fits-all" model is not applicable; each CMC program must be individually crafted to navigate the complex interplay of funding, regulatory expectations, and the practicalities of drug development. This strategic approach is essential as the pharmaceutical industry evolves. A robust CMC strategy is a critical determinant of a company's ability to successfully bring new therapies to market, especially for those operating on the cutting edge of biotechnology. Emerging biotech companies face unique challenges that require tailored CMC strategies. A phase-appropriate approach and a strong emphasis on planning and partnership can help these companies navigate the complexities of drug development, ensuring they can swiftly and successfully bring their innovations to market.

## Conflicts of Interest

The author declares no conflicts of interest regarding the publication of this paper.

## References


[1] (2023) Navigating the Small Molecule CMC Pathway: Strategies for Avoiding Regulatory Hurdles and Early Drug Development Pitfalls. https://xtalks.com/webinars/navigating-the-small-molecule-cmc-pathway-strategies-for-avoiding-regulatory-hurdles-and-early-drug-development-pitfalls/

[2] Sutherland, J.J., Woodhead, J.L. and Longo, J. (2021) Exploring Different Approaches to Improve the Success of Drug Discovery and Development Projects. *Future Journal of Pharmaceutical Sciences*, **7**, 25.

[3] (2023) Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization. https://www.pharmasalmanac.com

[4] Castellanos, M.M., Gressard, H., Li, X., Magagnoli, C., Moriconi, A., Stranges, D., *et al.* (2023) CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness. *Vaccines*, **11**, Article 1153. https://doi.org/10.3390/vaccines11071153

[5] McKinsey & Company (2023) Preclinical Development of New Medicines. https://www.mckinsey.com

[6] ICON (2023) CMC in Drug Development and Life Cycle Management. https://www.iconplc.com

[7] Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P.G. and Rabosio, E. (2020) The Endless Frontier? The Recent Increase of R & D Productivity in Pharmaceuticals. *Journal of Translational Medicine*, **18**, Article No. 162. https://doi.org/10.1186/s12967-020-02313-z

[8] Michaeli, D.T., Michaeli, T., Albers, S., Boch, T. and Michaeli, J.C. (2023) Special FDA Designations for Drug Development: Orphan, Fast Track, Accelerated Approval, Priority Review, and Breakthrough Therapy. *The European Journal of Health Economics*. https://doi.org/10.1007/s10198-023-01639-x

[9] U.S. Food and Drug Administration (FDA) (2023) Understanding Investigational Drugs for Patients. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers

[10] Steinmetz, K.L. and Spack, E.G. (2009) The Basics of Preclinical Drug Development for Neurodegenerative Disease Indications. *BMC Neurology*, **9**, S2. https://bmcneurol.biomedcentral.com

[11] U.S. Food and Drug Administration (2020) Investigational New Drug (IND) Application. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application

[12] U.S. Food and Drug Administration (2023) Overview of FDA expedited Programs for Serious Conditions. https://www.fda.gov/media/94063/download

[13] Marks, P. and Gottlieb, S. (2018) Balancing Safety and Innovation for Cell-Based Regenerative Medicine. *The New England Journal of Medicine*, **378**, 954-959.

[14] PowerPak (2023) The FDA Accelerated Drug Approval Process. https://journalce.powerpak.com/ce/the-fda-accelerated-drug-approval#:~:text=These%20approaches%20include%20priority%20review%2C%20a%20process%20that,1%20This%20article%20will%20discuss%20the%20AA%20program

[15] Shetty, Y.C. and Marathe, P.A. (2019) Accelerating Pharmaceutical Development through the Fast Track, Breakthrough Therapy, and Priority Review Designations.

*American Journal of Therapeutics*, **26**, e344-e352.

[16] Johnson, J. and Stevenson, R. (2021) Enhancing IND Approval Processes through Strategic CMC Practices. *Journal of Pharmaceutical Innovation*, **16**, 223-237. https://doi.org/10.1007/s12247-021-09509-x

[17] ICON plc (2023) CMC in Drug Development and Life Cycle Management. https://www.iconplc.com

[18] Hotha, K.K. (2023) Unleashing the Power of Innovation in CDMOs through Customer-Centricity and Culture of Service. *American Journal of Industrial and Business Management*, **13**, 234-246. https://doi.org/10.4236/ajibm.2023.134016

[19] Johnson, L. and Lee, H. (2020) Comprehensive Analytical Strategies in Drug Development. *American Journal of Pharmaceutical Education*, **84**, 758-769.

[20] Green, M.K. and Brown, L.T. (2022) Rapid Market Entry: Streamlined Development in the Pharmaceutical Industry. *Drug Development and Industrial Pharmacy*, **48**, 320-330.

[21] Davis, S. and Thompson, R. (2021) Enhancing Pharmaceutical Development through Customized Solutions. *Journal of Commercial Biotechnology*, **27**, 34-45.

[22] Evans, W.G. and Patel, A. (2019) Strategic Approaches to Early-Market Advantages in Biopharma. *Biotechnology Advances*, **37**, Article ID: 107384.

[23] Kim, Y. and Zhao, X. (2020) Expanding Market Base through Comprehensive Biopharma Strategies. *Journal of Business Venturing*, **35**, Article ID: 105982.

[24] European Medicines Agency (2024) ICH Q14 Analytical Procedure Development—Scientific Guideline. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5_en.pdf

[25] European Medicines Agency (2024) ICH Q2(R2) Validation of Analytical Procedures—Scientific Guideline. https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline

[26] U.S. Food and Drug Administration (2000) Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products

[27] Hotha, K.K., Reddy, S.P.K., Raju, V.K. and Ravindranath, L.K. (2013) Forced Degradation Studies: Practical Approach—Overview of Regulatory Guidance and Literature for the Drug Products and Drug Substances. *International Research Journal of Pharmacy*, **4**, 78-85. https://doi.org/10.7897/2230-8407.04517

[28] Hotha, K.K. (2023) Transforming Molecules into Medicines: Role of CDMOS in Phase-Appropriate Technology Transfers in Advancing Pharmaceutical Innovation. *Advances in Chemical Engineering and Science*, **13**, 203-223. https://doi.org/10.4236/aces.2023.133015